FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174265718> ?p ?o ?g. }

• W3174265718 abstract "Quiescent (G0) cells are a relevant fraction in cancers, which include dormant stem cells, and resist clinical therapy. G0 cells reveal changes in gene expression at the protein and translation levels. We previously identified that the translation mechanism is altered in G0 cancer cells. MicroRNAs—noncoding RNAs that target mRNAs to alter gene expression—associate with a key RNA-binding protein, and recruit non-canonical translation factors to mediate specific mRNA translation in G0. We find that G0 leukemic cells show similar proteome and translatome to cells isolated post-chemotherapy. These data suggest that specialized post-transcriptional mechanisms in G0 leukemic cells produce a distinct translatome to facilitate chemoresistance. To understand post-transcriptional regulation in chemoresistance, we compared global transcriptome, translatome and proteome in chemoresistant G0 acute monocytic leukemic (AML) cells. We find that chemotherapy or G0 leads to DNA damage responsive ATM and stress signaling, which alter post-transcriptional and translational mechanisms. ATM and stress activated p38 MAPK/MK2 increase AU-rich-element (ARE) bearing pro-inflammatory cytokine and immune gene mRNAs, by regulating a key ARE RNA binding protein and modifying canonical translation. AREs are present on 3′UTRs of tightly regulated cytokines to post-transcriptionally control their expression. Both rate limiting steps—tRNA recruitment and mRNA cap recognition—in canonical translation are altered. Stress signaling activates kinases that reduce canonical tRNA recruitment. This signaling also reduces mTOR activity in G0 and chemoresistant cells, which activates the cap complex inhibitor, eIF4EBP to impair canonical translation, leading to non-canonical translation of specific mRNAs with specialized cap binding and ribosome recruitment factors. These changes permit translation of ARE bearing pro-inflammatory cytokine TNFα, and immune modulators that promote survival. Co-inhibiting p38 MAPK and TNFα that promote anti-apoptosis— prior to or along with chemotherapy—decreases chemoresistance in AML cells, in vivo, and in patient samples, without affecting normal cells. Our studies reveal a pro-inflammatory subpopulation in AML that mediates resistance, enabled by DNA damage- and stress-regulated post-transcriptional and translational mechanisms that are mediated by AU-rich-elements and a critical ARE RNA binding protein. Disrupting ARE regulation reduces TNFα and chemoresistance, revealing AREs, the ARE RNA binding protein and non-canonical translation as regulators of chemoresistance. These studies reveal the importance of post-transcriptional regulation of pro-inflammatory genes in chemoresistance. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal." @default.
• W3174265718 created "2021-07-05" @default.
• W3174265718 creator A5000376011 @default.
• W3174265718 creator A5002949764 @default.
• W3174265718 creator A5006930456 @default.
• W3174265718 creator A5007240376 @default.
• W3174265718 creator A5009505227 @default.
• W3174265718 creator A5009723763 @default.
• W3174265718 creator A5014834463 @default.
• W3174265718 creator A5021342063 @default.
• W3174265718 creator A5033265658 @default.
• W3174265718 creator A5035548797 @default.
• W3174265718 creator A5038280749 @default.
• W3174265718 creator A5054654298 @default.
• W3174265718 creator A5059540252 @default.
• W3174265718 creator A5063619699 @default.
• W3174265718 creator A5069961391 @default.
• W3174265718 creator A5070808897 @default.
• W3174265718 creator A5071356246 @default.
• W3174265718 creator A5072193211 @default.
• W3174265718 creator A5074163638 @default.
• W3174265718 creator A5088797237 @default.
• W3174265718 date "2019-04-01" @default.
• W3174265718 modified "2023-09-27" @default.
• W3174265718 title "A specialized post‐transcriptional program in chemoresistant, quiescent cancer cells" @default.
• W3174265718 doi "https://doi.org/10.1096/fasebj.2019.33.1_supplement.629.8" @default.
• W3174265718 hasPublicationYear "2019" @default.
• W3174265718 type Work @default.
• W3174265718 sameAs 3174265718 @default.
• W3174265718 citedByCount "0" @default.
• W3174265718 crossrefType "journal-article" @default.
• W3174265718 hasAuthorship W3174265718A5000376011 @default.
• W3174265718 hasAuthorship W3174265718A5002949764 @default.
• W3174265718 hasAuthorship W3174265718A5006930456 @default.
• W3174265718 hasAuthorship W3174265718A5007240376 @default.
• W3174265718 hasAuthorship W3174265718A5009505227 @default.
• W3174265718 hasAuthorship W3174265718A5009723763 @default.
• W3174265718 hasAuthorship W3174265718A5014834463 @default.
• W3174265718 hasAuthorship W3174265718A5021342063 @default.
• W3174265718 hasAuthorship W3174265718A5033265658 @default.
• W3174265718 hasAuthorship W3174265718A5035548797 @default.
• W3174265718 hasAuthorship W3174265718A5038280749 @default.
• W3174265718 hasAuthorship W3174265718A5054654298 @default.
• W3174265718 hasAuthorship W3174265718A5059540252 @default.
• W3174265718 hasAuthorship W3174265718A5063619699 @default.
• W3174265718 hasAuthorship W3174265718A5069961391 @default.
• W3174265718 hasAuthorship W3174265718A5070808897 @default.
• W3174265718 hasAuthorship W3174265718A5071356246 @default.
• W3174265718 hasAuthorship W3174265718A5072193211 @default.
• W3174265718 hasAuthorship W3174265718A5074163638 @default.
• W3174265718 hasAuthorship W3174265718A5088797237 @default.
• W3174265718 hasConcept C104317684 @default.
• W3174265718 hasConcept C104397665 @default.
• W3174265718 hasConcept C105580179 @default.
• W3174265718 hasConcept C121608353 @default.
• W3174265718 hasConcept C145059251 @default.
• W3174265718 hasConcept C149364088 @default.
• W3174265718 hasConcept C150194340 @default.
• W3174265718 hasConcept C153911025 @default.
• W3174265718 hasConcept C162317418 @default.
• W3174265718 hasConcept C3675279 @default.
• W3174265718 hasConcept C39685955 @default.
• W3174265718 hasConcept C502942594 @default.
• W3174265718 hasConcept C54355233 @default.
• W3174265718 hasConcept C60644358 @default.
• W3174265718 hasConcept C62478195 @default.
• W3174265718 hasConcept C86554907 @default.
• W3174265718 hasConcept C86803240 @default.
• W3174265718 hasConcept C95444343 @default.
• W3174265718 hasConcept C96232424 @default.
• W3174265718 hasConceptScore W3174265718C104317684 @default.
• W3174265718 hasConceptScore W3174265718C104397665 @default.
• W3174265718 hasConceptScore W3174265718C105580179 @default.
• W3174265718 hasConceptScore W3174265718C121608353 @default.
• W3174265718 hasConceptScore W3174265718C145059251 @default.
• W3174265718 hasConceptScore W3174265718C149364088 @default.
• W3174265718 hasConceptScore W3174265718C150194340 @default.
• W3174265718 hasConceptScore W3174265718C153911025 @default.
• W3174265718 hasConceptScore W3174265718C162317418 @default.
• W3174265718 hasConceptScore W3174265718C3675279 @default.
• W3174265718 hasConceptScore W3174265718C39685955 @default.
• W3174265718 hasConceptScore W3174265718C502942594 @default.
• W3174265718 hasConceptScore W3174265718C54355233 @default.
• W3174265718 hasConceptScore W3174265718C60644358 @default.
• W3174265718 hasConceptScore W3174265718C62478195 @default.
• W3174265718 hasConceptScore W3174265718C86554907 @default.
• W3174265718 hasConceptScore W3174265718C86803240 @default.
• W3174265718 hasConceptScore W3174265718C95444343 @default.
• W3174265718 hasConceptScore W3174265718C96232424 @default.
• W3174265718 hasIssue "S1" @default.
• W3174265718 hasLocation W31742657181 @default.
• W3174265718 hasOpenAccess W3174265718 @default.
• W3174265718 hasPrimaryLocation W31742657181 @default.
• W3174265718 hasRelatedWork W1528734410 @default.
• W3174265718 hasRelatedWork W2001915927 @default.
• W3174265718 hasRelatedWork W2006583056 @default.
• W3174265718 hasRelatedWork W2075366669 @default.
• W3174265718 hasRelatedWork W2092959523 @default.
• W3174265718 hasRelatedWork W2132816368 @default.
• W3174265718 hasRelatedWork W2789780334 @default.

• next